Saturday, July 11, 2026

pharma · Oral Mucositis · Complex Cardiovascular Surgery With Cardiopulmonary Bypass

CSL Behring

CSL Behring is a pharma organization headquartered in Marburg, DE. Primary therapeutic focus areas include Oral Mucositis, Complex Cardiovascular Surgery With Cardiopulmonary Bypass, Rheumatoid Arthritis, Antibody-mediat

Marburg, DE HQ
EMA registrant Type
Company details
Status
Public
HQ
Marburg, DE
Programs
7
Drugs
6
Patents
25
Clinical program

BMS-945429 Placebo

Phase 2 · small molecule · Rheumatoid Arthritis

BMS-945429 Placebo for Rheumatoid Arthritis is a Phase 2 program (small_molecule) at CSL Behring GmbH with 1 ClinicalTrials.gov record(s).

← All CSL Behring GmbH projects Phase 2 small molecule completed

Internal code IM133-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
CSL Behring GmbH
Phase
Phase 2
Modality
small_molecule
Indication
Rheumatoid Arthritis
Status
completed
Trials
1

Clinical trials